We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > relatlimab

News List

Global ICIs Market Exceeds USD 30 Billion in 2021, with its Number and Indications Approved Entering an Outbreak Period Yi
April 11, 2022
Lately, Opdualag, a fixed-dose compound preparation of BMS consisting of LAG-3 inhibitor relatlimab and PD-1 monoclonal antibody nivolumab, was approved by FDA for the treatment of adults and pediatric patients aged 12 years and older with unresectable or
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma pharmatimes
March 31, 2021
Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma.